SAN DIEGO, Sept. 25, 2019 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will deliver a corporate presentation at the 2019 Cantor Global Healthcare Conference, being held

WASHINGTON, Sept. 25, 2019 /PRNewswire/ -- The National Resident Matching Program® (NRMP®) is pleased to announce that its national stakeholder conference, 

NEWARK, Calif., Sept. 25, 2019 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will present at the Cantor Global Healthcare Conference in New York.

BOSTON, Sept. 25, 2019 /PRNewswire/ -- XRHealth, formerly known as VRHealth, the leader in extended reality and therapeutic applications, today announced a partnership wi

OLDWICK, N.J., Sept. 25, 2019 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a clinical-stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that management will present at the 2019 Cantor Global Healthcare Conference on Wednesday, October 2, 2019, at 4:45 pm E.T. The conference is being h

CRANFORD, N.J., Sept. 25, 2019 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius") ("Company") (NASDAQ: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, today announced the pricing of an underwritten offering of 7,821,230 shares of its common stock (Common Stock) (or Common Stock equivalent) and common

TEL AVIV, Israel, Sept. 25, 2019 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) and (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, announced today dosing of the first patient in part 2 of the Phase 1/2a clinical study for AGI-134, a novel compound that evokes a direct anti-tumo

RAMAT HA SHARON, Israel, Sept. 25, 2019 /PRNewswire/ -- Body Vision Medical, a commercial-stage medical device company specializing in lung cancer diagnostics and treatment through real-time software technologies, announced that it has closed

JERUSALEM, Sept. 25, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces that two posters highlighting data from the Company's Phase 3 clinical development program for the Accordion Pill® Carbidopa/Levodopa (AP-CD/LD), were presented yesterday at the International Congress of Parkinson's and Movement Disord

EDMONTON, Sept. 25, 2019 /PRNewswire/ - OncoQuest Inc., a privately held, cancer immunotherapy company today announced that a Notice of Allowance was received from the U.S. Patent and Trademark Office (USPTO) for patent protection of the schedule of administration of our monoclonal anti-CA-125 antibody, mAb-B43.13, now known as oregovomab, in a specific schedule in combi